Novel adipokines, high molecular weight adiponectin and resistin, are associated with outcomes following lower extremity revascularization with autogenous vein

Journal of Vascular Surgery

Volumn 51, Issue 5, 2010, Pages 1152-1159

  Owens, Christopher D ^a   Kim, Ji Min ^a   Hevelone, Nathanael D ^a   Hamdan, Allen ^b   Raffetto, Joseph D ^c   Creager, Mark A ^d   Conte, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; ADIPOCYTOKINE; BIOLOGICAL MARKER;

ADULT; AFRICAN AMERICAN; AGED; AMPUTATION; ARTICLE; AUTOGRAFT; BLOOD SAMPLING; BYPASS SURGERY; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLAUDICATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT PATENCY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LEG; LEG REVASCULARIZATION; LIMB ISCHEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SAPHENOUS VEIN GRAFT; SURVIVAL; ANGIOGRAPHY; AUTOTRANSPLANTATION; BLOOD; CONFIDENCE INTERVAL; GRAFT SURVIVAL; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; TIME; TRANSPLANTATION; TREATMENT OUTCOME; VASCULAR SURGERY; VASCULARIZATION; VEIN;

ADIPOKINES; ADIPONECTIN; AGED; ANGIOGRAPHY; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; LONGITUDINAL STUDIES; LOWER EXTREMITY; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASES; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESISTIN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES; VEINS;

EID: 77952300550     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.12.051     Document Type: Article

References (36)

1. Owens CD, Ridker PM, Belkin M, Hamdan AD, Pomposelli F,Logerfo F, et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg 2007;45:2-9; discussion 9.
2. McDermott MM, Greenland P, Guralnik JM, Ferrucci L, Green D, Liu K, et al. Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease. Vasc Med 2004;9:107-15.
3. Owens CD, Ho KJ, Conte MS. Risk factors for failure of lower-extremity revascularization procedures: are they different for bypass and percutaneous procedures? Semin Vasc Surg 2008;21:143-53.
4. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290:1884-90.
5. Farin HM, Abbasi F, Reaven GM. Comparison of body mass index versus waist circumference with the metabolic changes that increase the risk of cardiovascular disease in insulin-resistant individuals. Am J Car-diol 2006;98:1053-6.
6. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-45.
7. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
8. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.
9. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
10. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Mat-subara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-9.
11. Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007;56: 459-67.
12. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409: 307-12.
13. Pang S, Le Y. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol 2006;3:29-34.
14. Owens CD, Rybicki FJ, Wake N, Schanzer A, Mitsouras D, Gerhard-Herman MD, Conte MS. Early remodeling of lower extremity vein grafts: inflammation influences biomechanical adaptation. J Vasc Surg 2008;47:1235-42.
15. Bonora E, Targher G,Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
16. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-38.
17. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007; 100:569-74.
18. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
19. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51.
20. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. Association of hypoadiponectinemia with impaired vasoreac-tivity. Hypertension 2003;42:231-4.
21. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006;188:384-90.
22. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
23. Schouten O, Hoeks SE, Goei D, Bax JJ, Verhagen HJ, Poldermans D. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery. J Vasc Surg 2009;49:435-41; discussion 441-2.
24. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-10.
25. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Rich-elsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010;95:911-9.
26. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-9.
27. Komai H, Shibata R, Juri M, Matsushita K, Ouchi N, Murohara T. Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease. J Vasc Surg 2009;50:95-9.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).JAMA. 2001; 285, 2486-97.
29. Pearson TA, Mensah GA, Hong Y, Smith SC Jr; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. Circulation 2004;110:e543-4.
30. Shyu KG, Chua SK, Wang BW, Kuan P. Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. J Biomed Sci 2009;16:50.
31. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279:48487-90.
32. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
33. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, etal. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006;69:76-85.
34. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-31.
35. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-62.
36. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152-62.